More Galleries
7 hot businesses to start now It's hard to predict what businesses will take off, but these startup ideas have been drawing tons of interest from entrepreneurs and their customers on Thumbtack.com. More
How will a minimum wage hike hit businesses? Thirteen states increased the minimum wage on Jan. 1, and President Obama supports raising the federal rate to $10.10. 4 small business owners weigh in on how an increase would affect them. More
America's favorite businesses From a science camp for girls to a kombucha brewer, communities around the country voted on their favorite small businesses. These 12 came out on top, each scoring a $250,000 grant from Chase and a trip to Google's headquarters. More

Special Offer
11 of 36
BACK NEXT
A novel treatment for a damaged heart
A novel treatment for a damaged heart
Gokul Kumar and Darius Kaullius
Team name: BioRegenix

School: University of Illinois at Chicago, College of Business Administration

Team members: Gokul Kumar, Darius Kaullius, Thomas Triantafillou

Concept: Acute Coronary Syndrome, an umbrella term for chronic heart-muscle injuries that put victims at risk for heart attacks, plagues 2.6 million Americans each year. BioRegenix, a startup formed by a group of medical students and MBAs at the University of Chicago at Illinois, offers a novel therapy to repair damaged heart tissue.

BioRegenix's CardioGen product combines a physical "scaffold" for stem-cell growth with a hormone that induces muscle expansion. BioRegenix's founders predict that this combination will stimulate stem cells already in the body to regenerate damaged tissue, thus repairing heart function.

BioRegenix faces steep odds. The team itself acknowledges that only 8% of pre-clinical pharmaceuticals succeed. But if it works, CardioGen could tap a massive market: Heart disease is the leading cause of death in the U.S.

Timeline: BioRegenix plans to continue its research work through the next two years, then begin the FDA approval process with Phase I clinical testing in 2010. - Mina Kimes

NEXT: A breakthrough board for snow bunnies

Last updated May 02 2008: 11:51 AM ET
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.